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by means of a smartphone. Sleep quality and nocturnal cough frequencies were measured every night
with the Pittsburgh Sleep Quality Index and by manually annotating coughs from smartphone audio
recordings. Primary endpoint was asthma control assessed with a weekly version of the Asthma Control
Test. Secondary endpoint was self-reported asthma attacks. Results Mixed-effects regression analyses
showed that nocturnal cough and sleep quality were statistically significantly associated with asthma
control on a between- and within-patient level (p < 0.05). Decision trees indicated that sleep quality
was more useful for detecting weeks with uncontrolled asthma (balanced accuracy (BAC) 68% vs 61%;
Δ sensitivity -12%; Δ specificity -2%), while nocturnal cough better detected weeks with asthma control
deteriorations (BAC 71% vs 56%; Δ sensitivity 3%; Δ specificity -34%). Cut-offs using both markers
predicted asthma attacks up to five days ahead with BACs between 70% and 75% (sensitivities 75 -
88% and specificities 57 - 72%). Conclusion Nocturnal cough and sleep quality have useful properties as
markers for asthma control and seem to have prognostic value for the early detection of asthma attacks.
Due to the limited study duration per patient and the pragmatic nature of the study, future research
is needed to comprehensively evaluate and externally validate the performance of both biomarkers and
their utility for asthma self-management.
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Introduction: Objective markers for asthma, that can be measured without extra patient 
effort, could mitigate current shortcomings in asthma monitoring. We investigated whether 
smartphone-recorded nocturnal cough and sleep quality can be utilized for the detection of 
periods with uncontrolled asthma or meaningful changes in asthma control and for the 
prediction of asthma attacks.
Methods: We analyzed questionnaire and sensor data of 79 adults with asthma. Data were 
collected in situ for 29 days by means of a smartphone. Sleep quality and nocturnal cough 
frequencies were measured every night with the Pittsburgh Sleep Quality Index and by 
manually annotating coughs from smartphone audio recordings. Primary endpoint was 
asthma control assessed with a weekly version of the Asthma Control Test. Secondary 
endpoint was self-reported asthma attacks.
Results: Mixed-effects regression analyses showed that nocturnal cough and sleep quality 
were statistically significantly associated with asthma control on a between- and within- 
patient level (p < 0.05). Decision trees indicated that sleep quality was more useful for 
detecting weeks with uncontrolled asthma (balanced accuracy (BAC) 68% vs 61%; Δ 
sensitivity −12%; Δ specificity −2%), while nocturnal cough better detected weeks with 
asthma control deteriorations (BAC 71% vs 56%; Δ sensitivity 3%; Δ specificity −34%). 
Cut-offs using both markers predicted asthma attacks up to five days ahead with BACs 
between 70% and 75% (sensitivities 75 - 88% and specificities 57 - 72%).
Conclusion: Nocturnal cough and sleep quality have useful properties as markers for 
asthma control and seem to have prognostic value for the early detection of asthma attacks. 
Due to the limited study duration per patient and the pragmatic nature of the study, future 
research is needed to comprehensively evaluate and externally validate the performance of 
both biomarkers and their utility for asthma self-management.
Keywords: asthma, digital biomarker, nocturnal cough, sleep quality, asthma control 
assessment, asthma attack prediction
Introduction
Asthma is one of the most prevalent chronic respiratory diseases. It affects an 
estimated 300 million people globally.1 Despite the availability of effective treat-
ment options, suboptimal asthma control is still common.2,3
To prevent potentially life-threatening asthma attacks, patients need to be aware of 
their actual asthma control and early warning signs of deterioration.2 However, prior 
research has found that patients’ subjective self-assessments are biased towards an 
overestimation of asthma control.4 For patients with a longer duration of illness, in 
particular, subjective assessments are of limited reliability.5 Furthermore, objective 
methods of asthma monitoring (eg, self-administered asthma control test (ACT6) or 
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peak flow monitoring) are considered impractical by 
patients7 and are still poorly adopted in practice.4
Novel objective markers, that can be measured without 
extra patient effort, could mitigate these shortcomings.8 
Nocturnal cough and sleep quality, for example, have 
been reported to be statistically associated with asthma 
control in cross-sectional studies.9–11 Research in the 
domain of mobile sensing demonstrated their measurabil-
ity by means of a smartphone’s built-in sensors.12,13
We investigated whether nocturnal cough and sleep 
quality may constitute useful markers for asthma. 
Expanding the findings of prior research, we first exam-
ined whether both markers are associated with asthma 
control in a longitudinal (ie, within-patient) setting. We 
then investigated whether both markers can enable the 
detection of periods with uncontrolled asthma or clinically 
meaningful deteriorations of asthma control, and predic-
tion of asthma attacks.
Methods
The study protocol of this two-center, longitudinal, 
observational study has already been published14 
(Clinicaltrials No: NCT03635710). Here, we report 
results on the association of nocturnal cough, sleep 
quality, asthma control, and asthma attacks (2nd 
study stage). Details about nocturnal cough character-
istics (1st study stage) will be published in a separate 
paper.15
The study has been reviewed and approved by the 
responsible ethics commission (“Ethikkommission 
Ostschweiz”, ID: 2017–01872). All patients provided writ-
ten informed consent. The study was conducted in accor-
dance with the Declaration of Helsinki.
Study Subjects
Adult patients with a history of asthma (Figure 1) were 
included between February 2018 and June 2019 in two 
study centers in Switzerland (the Lung Center of the 
Cantonal Hospital St. Gallen and the mediX Group prac-
tice Zurich in cooperation with the University of Zurich).
No treatments were administered or prescribed by the 
study personnel. All patients were treated during the study 
period according to current medical knowledge and prac-
tice by their usual health-care partner.
Figure 1 Study flowchart.
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Study Design
Study duration per patient was 29 days. On d1 and d29, 
medical assessments of patients were performed at the 
study centers. In the time between study center appoint-
ments, questionnaire and sensor data were collected in situ 
with a smartphone (Samsung Galaxy A3 2017, SM- 
A320FL) application based on MobileCoach.16,17
This work has four objectives: (1) to examine the 
statistical associations of both markers (ie, nocturnal 
cough and sleep quality) with asthma control, in particular 
with regard to within-patient associations; to investigate 
whether they enable detection of weeks, in which (2) 
patients had uncontrolled asthma or (3) clinically signifi-
cant deteriorations in asthma control occurred; and (4) to 
explore whether they can be used to predict asthma attacks 
in advance.
The study was powered to examine statistical associa-
tions between both markers and asthma control.14 Data 
from 79 patients could be analyzed after accounting for 
dropouts, so that the targeted sample size was missed by 6 
patients (Figure 1). Since the power analysis was based on 
conservative assumptions (ie, disregard of longitudinal 
measurements), the slightly smaller sample size likely 
sufficed for statistical analysis.
Measures
The study protocol14 contains a description of all measures 
we have obtained in the four study weeks per patient. 
Additional information on predictors and endpoints is pro-
vided in the online supplement (Supplementary Text S1).
Predictors
A patient’s sleep quality was assessed daily via an adapted 
version of the Pittsburgh Sleep Quality Index (PSQI18). 
Although devices for assessing sleep quality passively and 
with a higher temporal resolution are available,19 we 
decided to use a questionnaire-based assessment to reduce 
the burden for patients during the study (ie, patients had to 
fill out questions on the smartphone every morning either 
way). PSQI score was standardized on a scale from 0 
(worst possible sleep quality) to 1 (best possible sleep 
quality). In 2291 nights, the 79 patients slept rather well 
with an average sleep quality of 77.5% (SD = 15.2%; cf. 
Figure s1 in the online supplement for the distribution of 
average sleep quality scores per patient). Patients have 
completed the PSQI for 2250 nights (98.2%). For missing 
values, the patient mean was imputed (cf. Table s1 in the 
online supplement for the benchmarking of different impu-
tation methods).
Nocturnal cough frequencies of patients were obtained 
for every night by manually labelling audio recordings 
from the smartphone’s built-in microphone. On average, 
patients coughed 9.9 times per night (SD = 27.1) with 
a median of 1 c/n (IQR 0–8). Figure s2 in the online 
supplement provides an illustration of the distribution of 
the average nocturnal cough count per patient. Data were 
available for 2145 out of 2212 nights (97.0%). Missing 
values were imputed by means of a Kalman Smoother.
Endpoints
Primary endpoint was asthma control. A weekly version of 
the ACT6 assessed a patient’s level of asthma control 
retrospectively for a given week. Thus, four ACT mea-
surements per patient were obtained. We observed statis-
tically significant differences in ACT scores between 
seasons (Kruskal–Wallis’ H(3) = 8.76, p = 0.03): The 
lowest (worst) average scores occurred between February 
and April (M = 18.9, SD = 1.83), while the highest (best) 
scores were reported between November and January (M = 
21.5, SD = 1.29). Please refer to the online supplement for 
more information on seasonality, also with regard to the 
predictors (cf. Figures s3 – s5).
For the analysis of statistical associations (ie, objective 
(1) of the study), the raw ACT score was used. For objec-
tive (2), asthma was considered uncontrolled in weeks in 
which patients had an ACT score below 20 points.20 The 
target outcome of objective (3) was defined according to 
the minimally important difference of the ACT: a decrease 
of >2 points in the ACT was considered a clinically mean-
ingful deterioration in asthma control.21
Secondary endpoint was asthma attack days indicated 
through a “yes/no” questions for each day. Prior research 
has used “yes/no” questions for the self-reports of both 
asthma attacks22 and symptoms23 before. Both endpoints 
were reported by patients at the end of each study week, 
ie, on d8, d15, d22, and d29.
Data for the primary and secondary endpoint were 
available for 308 out of 316 study weeks (97.5%). No 
imputations were performed with regard to the endpoints.
Analysis
All data analyses were performed in R 3.5.1.24–28 
Additional information, including a table summarizing 
the analysis plan, is available in the online supplement 
(cf. Tables s2 and s3).
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For the analysis of objective (1) to (3), predictors were 
transformed and aggregated according to the ACT recall 
week, implying that predictors and outcome stem from the 
same time frame. For objective (4), days with asthma 
attacks were predicted with measurements from preceding 
days. Thus, predictions in a strictly temporal sense were 
only made in the context of objective (4).
Mixed-effects regressions27 were employed in the ana-
lysis of objective (1).
For the analysis of objective (2) and (3), decision trees 
based on recursive partitioning analysis29,30 were applied. 
Detections were internally validated with a 5-fold cross- 
validation scheme.31
For objective (4), optimal cut-offs of predictor variable 
values were identified for attack prediction in the train 
folds and applied to each test fold, which represented an 
8-fold cross-validation approach.
For objectives (2) to (4), averaged balanced accuracy 
(BAC; ie, mean of sensitivity and specificity) across all 
test folds (consisting of patients previously not seen by the 
model) was defined as the main evaluation metric. We 
further report sensitivity (ie, true positives/all positives) 
and specificity (ie, true negatives/all negatives).32
Data Sharing Statement
It is not intended to share individual participant data.
Results
Table 1 summarizes the baseline characteristics of the 94 
included patients.
Asthma Control and Asthma Attacks
For the analysis of statistical associations, raw ACT scores 
were considered. The 79 analyzed patients had a median 
ACT score of 21 points (IQR = 18–23) in the 308 available 
weeks (Figure s6 in the online supplement depicts the 
distribution of weekly ACT scores).
Table 1 Baseline Characteristics
Demographics and Body Composition
Age (years) 45 (30–59)
Male, no. (%) 41 (44%)
Female, no. (%) 53 (56%)
Height, cm 170 (163–176)
Weight, kg 71 (63–83)
Body mass index, kg/m2 25 (22–28)





Table 1 (Continued). 
Demographics and Body Composition
Lung function
FEV1, liters 2.9 (2.3–3.4)
FEV1, % predicted 88 (77–101)












Asthma control test at baseline, points 21 (19–23)
Asthma control at baseline, no. (%)
Controlled 66 (70%)





Exacerbations within last 12 months, no. (%)
No 34 (36%)
Yes 60 (64%)
● Number of exacerbations 2 (1–2)
● ED visits due to asthma 11 (13%)
● Hospitalizations due to asthma 4 (4%)
Asthma medication, no. (%) Prescribed Used
SAMA 5 (5%) 3 (3%)
SABA 52 (55%) 41 (44%)
ICS 86 (91%) 77 (82%)
LABA 78 (83%) 71 (76%)
LAMA 9 (10%) 8 (9%)
Theophylline 0 (0%) 0 (0%)
Systemic corticosteroids 1 (1%) 0 (0%)
LTRA 10 (11%) 10 (11%)
Anti-IgE 0 (0%) 0 (0%)
Anti-IL5 2 (2%) 2 (2%)
Note: Data are expressed as median (interquartile range) unless stated otherwise. 
Abbreviations: No., number; FEV1, forced expiratory volume in 1 second; FeNO, 
fraction of nitric oxide in exhaled air; Ppb, parts per billion; GINA, global initiative 
for asthma; SAMA, short-acting muscarinic antagonist; SABA, short-acting beta- 
agonist; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long- 
acting muscarinic antagonist; LTRA, leukotriene-receptor-antagonist; IgE, immuno-
globulin E; IL5, interleukin-5; ED, emergency department; ACE, angiotensin- 
converting enzyme.
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As the second objective, weeks with uncontrolled 
asthma were detected. Asthma was controlled in 192 
weeks and uncontrolled in 116 weeks.
As the third objective, weeks with deteriorations in 
asthma control were detected. Changes in weekly asthma 
control could be calculated for 227 weeks. Clinically sig-
nificant deteriorations occurred in 29 weeks in 25 patients.
Finally, the fourth objective was to investigate the 
prediction of asthma attacks. Twelve patients registered 
35 attack days (mean = 2.9 days, SD = 2.5). Eight asthma 
attacks remained in a total of 2004 study days after keep-
ing only the first attack day per patient and excluding all 
patients with attacks in the first study week.
Objective 1: Statistical Associations of 
Nocturnal Cough and Sleep Quality with 
Asthma Control Using Mixed Effect 
Regression Modelling
All regression coefficients, regardless of variable center-
ing, were statistically significantly associated with asthma 
control (p < 0.05; cf. Table 2). Thus, patients, who 
coughed more/had worse sleep quality, tended to have 
worse asthma control (between-patient) and increases in 
nocturnal cough/decreases in sleep quality were statisti-
cally associated with decreases in asthma control in the 
same time and patient (within-patient). Interestingly, we 
have observed no statistical interaction between nocturnal 
cough and sleep quality when modelling their associations 
with asthma control (B = −.14, t(271.34) = −1.06, ns). 
Additional correlational analyses (Figure s7 for within- 
patient correlations between nocturnal cough and sleep 
quality and Figure s8 for correlations between cough 
based on subsegments of the night and asthma control; 
Supplementary Text S2) and the complete regression 
results table (Table s4) are available in the online supple-
ment (Supplementary Text S3).
Objectives 2–4: Cross-Validated Models 
for the Detection or Prediction of 
Asthma Endpoints
Table 3 contains the results of all cross-validated models 
(additional result metrics can be found in Table s5 of the 
online supplement; also Supplementary Text S3). We con-
sidered cough of the first half hour of bedtime as 
a separate predictor set, since most coughs occurred in 
this time frame (a second paper contains a detailed discus-
sion on the prevalence of nocturnal cough including pos-
sible explanations for the increased incidence of cough in 
the beginning of the night).15 We also included coughs of 
the remaining night (ie, after the first half hour of bedtime) 
as an additional predictor set. Since multiple variables 
have been used for growing the decision trees in objective 
(2) and (3), we facilitate model interpretation by providing 
estimates for the importance of each variable in the online 
supplement (Table s6).
For the second objective (ie, detection of weeks with 
uncontrolled asthma), we found that none of the five pre-
dictor sets achieved balanced accuracies of 70%. Sleep 
quality (BAC = 68%), however, was more useful for this 
objective than nocturnal cough (BAC = 60–62%). 
Combining predictor sets has not yielded an increase in 
prediction performance.
For the third objective (ie, detection of weeks with clini-
cally meaningful deteriorations in asthma control), the pat-
tern was inverted: Nocturnal cough (BAC = 71%) 
outperformed sleep quality (BAC = 56%) by a considerable 
margin. Interestingly, coughs within the first half hour of 
bedtime performed substantially worse than the entire night 
of cough (ΔBAC = −17%), while coughs after the first 
half hour of bedtime performed only slightly worse than the 
entire night (ΔBAC = −6%). Furthermore, combining pre-
dictors resulted in a decreased monitoring performance in 
comparison to nocturnal cough of the entire night.
Table 2 Statistical Associations of Nocturnal Cough and Sleep 
Quality with Asthma Control Using Mixed Effect Regression 
Modelling



























Marginal R2 a 0.14 0.25 0.29
Notes: Unstandardized beta (B) values are depicted. Square brackets contain the 
95% confidence interval. Nocturnal cough values are weekly sums of the log- 
transformed cough count (a doubling of the weekly nocturnal cough frequency 
within a patient is associated with a decrease of 0.32/.28 points in the ACT test). 
Sleep quality are weekly sums of the inverted daily sleep quality score standardized 
from 0% to 100% (a weekly decrease of 100 points or an average daily decrease of 
14.29 points within a patient is associated with a decrease of 1.01/.85 points in the 
ACT score). N = 308 weeks. aVariance explained by the predictors.33 *p<0.05. 
**p<0.01 ***p<0.001.
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The fourth objective was prediction of asthma attacks. 
BACs of 70% were achieved for subsegments of nocturnal 
cough three and four days ahead of the attack. Sleep 
quality was close to a BAC of 70% three to four days 
ahead of the attack. Combining predictor sets increased 
prognostic performance, regardless whether cough of the 
entire night (BACs of ≥70% for d0 – d−4; cf. Figure 2A) or 
cough within (BACs of ≥70% for d−3 – d−5; cf. Figure 2B) 
or after (BACs of ≥70% for d0 and d−2 – d−4; cf. Figure 
2C) the first half hour of bedtime was considered.
Discussion
In this study, smartphone-recorded nocturnal cough and 
sleep quality were systematically investigated as markers 
for asthma control and asthma attacks. We found that both 
markers could be potentially useful for monitoring asthma 




Detection of Weeks with 
Uncontrolled Asthma 
(O2)a,b
Detection of Weeks with 
Deteriorations in Asthma 
Control (O3)a,c
Prediction of Asthma Attacks X Days (dx) Before 
the Event (O4)d,e
d0 d−1 d−2 d−3 d−4 d−5 d−6 d−7
Sleep quality
BAC 0.68 0.56 0.68 0.65 0.66 0.69 0.68 0.63 0.57 0.46
Sensitivity 0.66 0.63 0.75 0.62 0.62 1 0.62 0.50 0.50 0.12
Specificity 0.69 0.48 0.61 0.69 0.70 0.38 0.73 0.76 0.65 0.79
Nocturnal cough (entire night)
BAC 0.61 0.71 0.63 0.69 0.62 0.67 0.59 0.58 0.53 0.40
Sensitivity 0.54 0.60 0.62 0.75 0.62 0.75 0.50 0.50 0.50 0
Specificity 0.67 0.82 0.63 0.63 0.61 0.58 0.68 0.66 0.57 0.79
Nocturnal cough (first 30 minutes after going to bed)
BAC 0.62 0.54 0.64 0.64 0.64 0.64 0.70 0.61 0.45 0.62
Sensitivity 0.59 0.35 0.62 0.62 0.62 0.62 0.75 0.62 0.12 0.50
Specificity 0.64 0.74 0.66 0.66 0.66 0.66 0.66 0.60 0.78 0.73
Nocturnal cough (after 30 minutes until end of night)
BAC 0.60 0.65 0.69 0.65 0.65 0.71 0.60 0.50 0.64 0.40
Sensitivity 0.47 0.45 0.62 0.75 0.75 0.88 0.50 0.50 0.75 0
Specificity 0.72 0.84 0.75 0.55 0.55 0.55 0.69 0.50 0.53 0.79
Sleep quality and nocturnal cough (entire night) combined
BAC 0.68 0.65 0.72 0.70 0.71 0.72 0.72 0.64 0.67 0.45
Sensitivity 0.66 0.48 0.88 0.75 0.75 0.75 0.75 0.50 0.62 0.25
Specificity 0.69 0.81 0.57 0.64 0.66 0.69 0.69 0.77 0.71 0.65
Sleep quality and nocturnal cough (first 30 minutes after going to bed) combined
BAC 0.68 0.55 0.64 0.65 0.63 0.72 0.74 0.71 0.58 0.40
Sensitivity 0.66 0.62 0.88 0.62 0.62 0.75 0.75 0.75 0.50 0.25
Specificity 0.69 0.48 0.41 0.67 0.64 0.69 0.72 0.68 0.66 0.55
Sleep quality and nocturnal cough (after 30 minutes until end of night) combined
BAC 0.68 0.57 0.73 0.69 0.70 0.72 0.72 0.64 0.67 0.52
Sensitivity 0.66 0.29 0.88 0.75 0.75 0.75 0.88 0.50 0.62 0.25
Specificity 0.69 0.84 0.59 0.64 0.66 0.69 0.56 0.78 0.71 0.80
Notes: All reported figures are averages over the five (O2 and O3) or eight (O4) folds. aModel: Decision Tree. bPositive outcome class: Uncontrolled asthma (ie, ACT score 
< 20; 116 out of 308 study weeks). cPositive outcome class: Clinically meaningful deterioration in asthma control (ie, a decrease in ACT score by > 2 points; 29 out of 227 
study weeks). dModel: Cut-offs. ePositive outcome class: Asthma attack (ie, 8 out of 2008 study days). ACT, Asthma Control Test. BAC, Balanced accuracy (values over 0.70, 
a threshold for usefulness,34 are printed in bold). 
Abbreviation: O, objective.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                     
Journal of Asthma and Allergy 2020:13 674






























































































Powered by TCPDF (www.tcpdf.org)
control. Combining both markers enhanced prognostic 
performance up to five days ahead of an asthma attack.
We replicated the between-patient statistical associa-
tions of nocturnal cough and sleep quality with asthma 
control reported by prior research. Marsden et al described 
weak to moderate correlations between nocturnal cough of 
a single night and asthma control.11 Luyster and collea-
gues have found similar cross-sectional correlation 
strengths with regard to sleep quality.10 With longitudinal 
data, however, we found stronger associations and were 
able to show that they hold for the within-patient level.
Our declining asthma attack prediction performance over 
time converges with prior descriptions of symptom 
deteriorations in developing asthma attacks. Tattersfield and 
colleagues descriptively investigated 425 severe attacks in 
the two weeks prior to the attack.35 A decline in symptoms 
and peak expiratory flow (PEF) “occurred gradually 
between day −10 and day −3 and then more rapidly”.
From a clinical point of view, long-term goals of 
asthma management are symptom control and risk reduc-
tion of asthma exacerbations and asthma-related deaths.2 
Asthma attacks can be fatal and are more common and 
more severe when asthma is not well controlled. Regular, 
objective assessment of asthma control is therefore a key 
element of successful asthma management. By recording 
markers of asthma control effortless and patient-friendly, 
Figure 2 Asthma attack prediction results of cut-offs based on the entire night (A), cough of first 30 minutes of bedtime (B), and cough after 30 minutes of bedtime (C). No 
subsegments of the night could be extracted for sleep quality. Trend lines were estimated through local polynomial regression. Black lines at 0.50 indicate the balanced 
accuracy of a model that always predicts the same class.
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for example, via a smartphone as employed in this study, 
access to objective assessments of asthma control can be 
facilitated. For example, we were able to show that deep 
learning models trained on data from this study can detect 
and count nocturnal cough automatically with 
a comparable accuracy to human annotators.36
However, the accuracies presented in this paper for 
detecting and predicting relevant asthma outcomes do not 
warrant the use of nocturnal cough and sleep quality as self- 
contained biomarkers for asthma management. The limiting 
factors for marker performance remain unclear. Possible 
reasons are the pragmatic study design with a limited study 
duration per patient and a smartphone-based data collection 
that is prone to operating errors, a sample characterized by 
rather well-controlled and intermittent-to-mild asthma, and 
disease-related reasons such as asthma’s heterogeneity,3 
which could limit marker applicability for certain asthma 
phenotypes and would result in an overall decreased marker 
performance if applied to the entire patient population.
Despite the moderate accuracies of our detection and 
prediction models based on nocturnal cough and sleep 
quality, we argue that both markers may be useful for 
asthma self-management. As part of its overall objective 
of increasing asthma control and preventing attacks, the 
GINA guideline recommends patients to monitor their 
symptoms.2 The associations with asthma outcomes 
reported in this paper suggest that nocturnal cough and 
sleep quality may indeed be relevant parameters for 
asthma symptom self-monitoring. Furthermore, their mod-
erate accuracies as self-contained biomarkers could be 
offset if assessments are subsequently confirmed by more 
accurate methods. Honkoop and colleagues found that 
action points based on PEF and symptom questionnaires 
enabled highly accurate early detection of asthma 
attacks.37 Thus, passively measured nocturnal cough and 
sleep quality could serve as additional cues for active 
monitoring based on action points. More specifically, 
objective cues for initiating active monitoring could enrich 
patients’ subjective self-assessments, which have been 
reported to be biased.5 Future research should investigate 
the efficacy and effectiveness of such a two-stage monitor-
ing strategy empirically. In the long-term application of 
both markers in practice, we suspect that nocturnal cough 
might emerge as the more robust and useful marker due to 
its inherently higher specificity to the respiratory system 
and due to a possible confounding treatment effect of oral 
corticosteroids (improvement in asthma outcomes2 accom-
panied by a simultaneous impairment of sleep quality).38
Strengths and Limitations
This is the first longitudinal study to examine the utility of 
nocturnal cough and sleep quality as markers for asthma. 
By defining lenient eligibility criteria and collecting 
patient data in situ, the presented results are characterized 
by high external validity. In a more controlled setting, we 
would expect higher performance figures due to more 
reliable measurements. Furthermore, by taking advantage 
of prior research on ACT cut-offs for different classifica-
tion purposes,20,21 we were able to investigate the utility of 
both candidate markers from multiple perspectives.
However, high external validity comes at the expense 
of compromised internal validity: we included patients 
with self-reported physician-diagnosed asthma and mod-
elled patients’ subjective assessments, which likely intro-
duced noise into our analysis, for example, due to varying 
definitions of asthma attacks between patients. Finally, the 
prognostic performance results have to be interpreted cau-
tiously due to the low number of observed asthma attacks.
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